BEXTRA Drug Patent Profile

When do Bextra patents expire, and what generic alternatives are available?

Bextra is a drug marketed by Gd Searle and is included in one NDA.

The generic ingredient in BEXTRA is valdecoxib. Additional details are available on the valdecoxib profile page.

Summary for BEXTRA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for BEXTRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-002	Nov 16, 2001		DISCN	No	No
Gd Searle	BEXTRA	valdecoxib	TABLET;ORAL	021341-003	Nov 16, 2001		DISCN	No	No

International Patents for BEXTRA

See the table below for patents covering BEXTRA around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	103155
Denmark	0809636
Slovakia	283558
Australia	4093697

Supplementary Protection Certificates for BEXTRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0809636	SPC/GB03/022	United Kingdom		PRODUCT NAME: VALDECOXIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/244/001-024 20030327; UK EU/1/02/239/001-024 20030327; UK EU/1/02/242/001-024 20030327
0809636	300128	Netherlands
0809636	C300128	Netherlands		PRODUCT NAME: VALDECOXIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH ACCEPTABEL ZOUT; REGISTRATION NO/DATE: EU/1/02/239/001 - EU/1/02/239/024, EU/1/02/242/001 - EU/1/02/242/024, EU/1/02/244/001 - EU/1/02/244/024 20030317
0809636	SPC011/2003	Ireland		SPC011/2003: 20030604, EXPIRES: 20160212

BEXTRA Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is BEXTRA?

BEXTRA is the brand name for valdecoxib, a nonsteroidal anti-inflammatory drug (NSAID) developed by Pfizer. It was approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea. The drug’s mechanism centers on selective COX-2 inhibition, aiming to reduce gastrointestinal side effects common to traditional NSAIDs.

What Is the Historical Context and Market Status for BEXTRA?

BEXTRA gained U.S. approval in 2001 but was voluntarily withdrawn from the market in 2005. The withdrawal followed reports of serious cardiovascular risks such as myocardial infarction and stroke linked to valdecoxib, similar to other COX-2 inhibitors like celecoxib. Pfizer’s decision was based on safety concerns, despite the drug’s initial market success and sales peaks of approximately $300 million annually before withdrawal.

What Were the Key Development and Regulatory Milestones?

• 2001: FDA approval of BEXTRA (valdecoxib).
• 2004: Post-marketing reports of adverse cardiovascular events began to surface.
• 2005: Pfizer voluntarily withdraws BEXTRA from all markets due to safety concerns.
• Post-withdrawal: Pfizer and other companies re-evaluate COX-2 inhibitor safety, leading to increased regulatory scrutiny.

What Are the Patent and Intellectual Property (IP) Rights?

Pfizer held patents around the use and synthesis of valdecoxib. The original patent expiration was scheduled for 2012 but was effectively nullified due to safety issues and market withdrawal. No generic versions entered the market before the discontinuation. Patent challenges and secondary patents are unlikely, given the market’s decline and safety concerns.

What Are the Current Regulatory and Market Advocacy Landscapes?

No current FDA approvals exist for BEXTRA or its generics. The drug’s withdrawal limits any immediate regulatory pathway for re-entry. No significant advocacy for resuming BEXTRA’s market presence exists, primarily due to safety concerns and the availability of safer alternatives.

Could BEXTRA or Similar Compounds Re-enter the Market?

Re-entry would require:

• Demonstration of improved safety profile through reformulation or biomarkers.
• New clinical trials indicating risk reduction.
• Regulatory approval, which is unlikely without substantial safety improvements.

The market interest for BEXTRA is negligible, as generic NSAIDs like ibuprofen and naproxen are available at lower cost and with well-characterized safety profiles.

What Are the Competitive and Market Dynamics?

The NSAID market is highly competitive with established drugs:

• Ibuprofen (Advil, Motrin): Dominant OTC NSAID.
• Naproxen (Aleve): Widely used OTC.
• Celecoxib (Celebrex): A COX-2 inhibitor still on market, with tight label restrictions, but fewer cardiovascular concerns than BEXTRA.

The cardiovascular safety profile of COX-2 inhibitors remains a critical concern, limiting the scope for reformulation or new development in this class.

What Are The Investment Implications?

Investing in BEXTRA reentry or new COX-2 inhibitors faces high regulatory, safety, and market hurdles. Pfizer's withdrawal reduces the drug's revenue potential drastically. Resources might be better allocated toward developing safer, selective anti-inflammatory agents with demonstrated cardiovascular safety.

What Are The Key Takeaways?

• BEXTRA was withdrawn in 2005 due to cardiovascular risks linked to COX-2 inhibitors.
• No current regulatory pathway exists for BEXTRA; market potential is near zero.
• Market dynamics favor drugs with proven safety profiles and lower risk of adverse cardiovascular events.
• Developing new COX-2 inhibitors would require overcoming substantial safety hurdles validated by rigorous clinical data.
• Pfizer’s safety controversies influence investor perceptions in COX-2 inhibitor development.

FAQs

1. Can BEXTRA be re-approved for use?
Re-approval is unlikely without significant reformulation and safety validation addressing cardiovascular risks.

2. Are there ongoing lawsuits related to BEXTRA’s safety?
Legal actions were initiated during its market presence, but the company settled many claims and withdrew the drug before extensive litigation.

3. Could a re-formulated version of valdecoxib enter the market?
Requires demonstrating significantly improved safety, which remains unproven.

4. What alternatives exist for the indications BEXTRA targeted?
NSAIDs like ibuprofen and naproxen are OTC options. Prescription alternatives include celecoxib, with a different safety profile.

5. Is there investor interest in developing new COX-2 inhibitors?
High safety concerns limit investment, and the market favors drugs with established safety profiles.

References

1. FDA Approval Package for BEXTRA (valdecoxib), 2001.
2. Pfizer Press Release, 2005, on withdrawal of BEXTRA.
3. FDA Public Health Advisory, 2004, on cardiovascular risks associated with COX-2 inhibitors.
4. Market data on NSAID sales and market share, 2022.
5. Clinical data on COX-2 safety profiles, PubMed, 2000–2020.